Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Alfredo Budillon

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6330-6053; OpenAlex author ID A5035710316. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
30
Papers, trials and grants by year

2011: 1 paper · 2012: 2 papers · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 2 papers · 2023: none · 2024: 2 papers · 2025: 1 paper · 2026: 1 paper

Papers 9

  1. Standardized workflow enables reproducibility of drug synergism detection: Results from a multi-center in vitro ring test on complex drug combinations in pancr… Last author DOI 10.1016/j.biopha.2026.119575↗
  2. Drug Repurposing in Pancreatic Cancer: A Multi-Stakeholder Perspective to Improve Treatment Options for Pancreatic Cancer Patients. Co-author DOI 10.2147/cmar.s483151↗
  3. Randomized phase 2 study of valproic acid combined with simvastatin and gemcitabine/nab-paclitaxel-based regimens in untreated metastatic pancreatic adenocarci… Co-author DOI 10.1186/s12885-024-12936-w↗
  4. The cross-talk between the macro and micro-environment in precursor lesions of pancreatic cancer leads to new and promising circulating biomarkers. Co-author DOI 10.1186/s13046-024-03117-5↗
  5. HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation. Last author DOI 10.1186/s13046-022-02295-4↗
  6. Correction to: HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation. Last author DOI 10.1186/s13046-022-02324-2↗
  7. The PPAR-γ agonist troglitazone antagonizes survival pathways induced by STAT-3 in recombinant interferon-β treated pancreatic cancer cells. Co-author DOI 10.1016/j.biotechadv.2011.08.001↗
  8. Pancreatic cancer: between bench and bedside. First author DOI 10.2174/138945012800564130↗
  9. Modulation of pancreatic cancer chemoresistance by inhibition of TAK1. Co-author DOI 10.1093/jnci/djr243↗

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Maria Serena Roca · 5 shared papers, 2022–2026 · strength 0.87
  2. Antonio Avallone · 3 shared papers, 2022–2024 · strength 0.42
  3. Claudia Fuchs · 2 shared papers, 2024–2025 · strength 0.37
  4. Tero A. Aittokallio · 1 shared paper, 2026 · strength 0.26
  5. Veronica Barile · 1 shared paper, 2026 · strength 0.26
  6. Violeta V. Stoyanova-Beninska · 1 shared paper, 2025 · strength 0.20
  7. Stephen Bigelsen · 1 shared paper, 2025 · strength 0.20
  8. Alfredo Carrato · 1 shared paper, 2025 · strength 0.20
  9. Ilse Rooman · 1 shared paper, 2025 · strength 0.20
  10. Luca Cardone · 1 shared paper, 2025 · strength 0.20
  11. Evelyn Hewitt · 1 shared paper, 2025 · strength 0.20
  12. Carla Mottini · 1 shared paper, 2024 · strength 0.20
  13. Damiano D. Caputo · 1 shared paper, 2024 · strength 0.20
  14. Giovanni Blandino · 1 shared paper, 2024 · strength 0.20
  15. Giulio Caracciolo · 1 shared paper, 2024 · strength 0.20
  16. Giulia Piaggio · 1 shared paper, 2024 · strength 0.20
  17. Christian P. Pilarsky · 1 shared paper, 2024 · strength 0.20
  18. Francesca Foschini · 1 shared paper, 2024 · strength 0.16
  19. Marina Macchini · 1 shared paper, 2024 · strength 0.16
  20. Giampaolo Tortora · 1 shared paper, 2024 · strength 0.16
  21. Michele Reni · 1 shared paper, 2024 · strength 0.16
  22. Davide Melisi · 2 shared papers, 2011–2012 · strength 0.09
  23. James L. Abbruzzese · 1 shared paper, 2011 · strength 0.03
  24. Jianhua Ling · 1 shared paper, 2011 · strength 0.03
  25. Paul J. Chiao · 1 shared paper, 2011 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.